We also provide proof‐of‐principle evidence for the translatability of the results by demonstrating significant in vivo intracranial tumor growth inhibition by orally dosed triplet therapy combining AKT and PDK inhibition with PP2A reactivation. Here, AKT1 is linked to neoplasm.